{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-096103","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2025-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.971567+00:00","generated_at":"2026-05-17T04:55:58.631628+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"David Moore joins Corvus board as Class III director through 2028; gets 30K option grant","bullets":["David Moore appointed as Class III director, term expires at 2028 annual meeting.","Moore will serve on Compensation Committee ($6K/yr) and Nominating Committee ($4K/yr).","Receives $35K annual retainer and initial option to purchase 30,000 shares of common stock.","Appointment effective October 2, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-096103","json":"https://secwatch.observer/filing/0001104659-25-096103.json","markdown":"https://secwatch.observer/filing/0001104659-25-096103.md","text":"https://secwatch.observer/filing/0001104659-25-096103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000110465925096103/0001104659-25-096103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000110465925096103/crvs-20251002x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:55:58.631628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}